Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit

Rocket Pharmaceuticals, Inc. RCKT ("Rocket"), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is scheduled to present on Wednesday, November 13, 2019, at 2:15 p.m. Eastern Time at the Barclays Gene Editing & Gene Therapy Summit, New York, N.Y.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. RCKT ("Rocket") is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket's multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's clinical programs using LVV-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket's first clinical program using AAV-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rocket's pre-clinical pipeline program is for Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. For more information about Rocket, please visit www.rocketpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005218/en/